dapsone has been researched along with Borderline Lepromatous in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The World Health Organization (WHO) recommends multidrug therapy (MDT) with rifampicin, dapsone, and clofazimine for treating leprosy, which is based on very low-quality evidence." | 5.41 | Seventy years of evidence on the efficacy and safety of drugs for treating leprosy: a network meta-analysis. ( Bao, F; Chen, J; Dong, Y; Fan, Y; Gao, L; Ji, Z; Kong, J; Li, B; Liu, A; Liu, M; Luo, S; Ma, W; Peng, L; Song, J; Wu, X; Yang, J, 2023) |
| "In this study, the authors compare plasma dapsone trough levels of multibacillary leprosy subjects stratified by body mass index (BMI) to evaluate if obesity plays a significant role on drug levels." | 3.80 | Dapsone and body mass index in subjects with multibacillary leprosy. ( Araujo, EC; Brasil, LM; Dias, RM; Ferreira, MV; Moura, FM; Vieira, JL, 2014) |
| "This study sought to verify the correlation between leprosy types and the adverse effects of treatment drugs." | 2.77 | Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects. ( Almeida, PC; Bührer-Sékula, S; Cruz, R; Gonçalves, Hde S; Moraes, ME; Penna, GO; Pontes, MA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 14 (82.35) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Chew, R | 1 |
| Woods, ML | 1 |
| Yang, J | 1 |
| Kong, J | 1 |
| Li, B | 1 |
| Ji, Z | 1 |
| Liu, A | 1 |
| Chen, J | 1 |
| Liu, M | 1 |
| Fan, Y | 1 |
| Peng, L | 1 |
| Song, J | 1 |
| Wu, X | 1 |
| Gao, L | 1 |
| Ma, W | 1 |
| Dong, Y | 1 |
| Luo, S | 1 |
| Bao, F | 1 |
| Penna, GO | 2 |
| Bührer-Sékula, S | 2 |
| Kerr, LRS | 1 |
| Stefani, MMA | 1 |
| Rodrigues, LC | 1 |
| de Araújo, MG | 1 |
| Ramos, AMC | 1 |
| de Andrade, ARC | 1 |
| Costa, MB | 1 |
| Rosa, PS | 1 |
| Gonçalves, HS | 1 |
| Cruz, R | 2 |
| Barreto, ML | 1 |
| Pontes, MAA | 1 |
| Penna, MLF | 1 |
| Pawar, M | 1 |
| Zawar, V | 1 |
| Kumavat, S | 1 |
| Daga, S | 1 |
| Craig, J | 1 |
| MacRae, C | 1 |
| Melvin, RG | 1 |
| Boggild, AK | 1 |
| Weberschock, T | 1 |
| Göttig, S | 1 |
| Moura, FM | 1 |
| Dias, RM | 1 |
| Araujo, EC | 1 |
| Brasil, LM | 1 |
| Ferreira, MV | 1 |
| Vieira, JL | 1 |
| El Morabite, K | 1 |
| Tbatou, F | 1 |
| Ait Ourhroui, M | 1 |
| Senouci, K | 1 |
| Hassam, B | 1 |
| Guerrero, MI | 1 |
| Colorado, CL | 1 |
| Torres, JF | 1 |
| León, CI | 1 |
| Shen, J | 1 |
| Yan, L | 1 |
| Yu, M | 1 |
| Li, J | 1 |
| Yu, X | 1 |
| Zhang, G | 1 |
| Ozturk, Z | 1 |
| Tatliparmak, A | 1 |
| Becker, L | 1 |
| Kowalewski, C | 1 |
| Martin, JM | 1 |
| Hall, JM | 1 |
| Torske, KR | 1 |
| Kahn, MA | 1 |
| Moreland, AA | 1 |
| Moschella, SL | 1 |
| Maghanoy, A | 1 |
| Mallari, I | 1 |
| Balagon, M | 2 |
| Saunderson, P | 1 |
| Ravanes, JM | 1 |
| Cellona, RV | 1 |
| Abalos, RM | 1 |
| Walsh, GP | 1 |
| Walsh, DS | 1 |
| Gonçalves, Hde S | 1 |
| Pontes, MA | 1 |
| Almeida, PC | 1 |
| Moraes, ME | 1 |
| Cunha, Mda G | 1 |
| Virmond, M | 1 |
| Schettini, AP | 1 |
| Cruz, RC | 1 |
| Ura, S | 1 |
| Ghuidella, C | 1 |
| Viana, Fdos R | 1 |
| Avelleira, JC | 1 |
| Campos, AA | 1 |
| Filho, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients[NCT00669643] | Phase 4 | 859 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for dapsone and Borderline Lepromatous
| Article | Year |
|---|---|
Seventy years of evidence on the efficacy and safety of drugs for treating leprosy: a network meta-analysis.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprostatic Agents; Leprosy; Leprosy, Multi | 2023 |
Leprosy treatment during pregnancy and breastfeeding: A case report and brief review of literature.
Topics: Adult; Breast Feeding; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprostatic | 2017 |
4 trials available for dapsone and Borderline Lepromatous
| Article | Year |
|---|---|
Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brazil; Child; Child, Preschool; Clofazimine; Dapsone; D | 2017 |
Longitudinal ocular survey of 202 Filipino patients with multi-bacillary (MB) leprosy treated with 2 year WHO-multiple drug therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Clofazimine; Dapsone; Drug Ther | 2011 |
Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects.
Topics: Adolescent; Adult; Aged; Child; Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprostatic | 2012 |
OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil.
Topics: Adolescent; Adult; Animals; Brazil; Clofazimine; Dapsone; Double-Blind Method; Drug Therapy, Combina | 2012 |
11 other studies available for dapsone and Borderline Lepromatous
| Article | Year |
|---|---|
Multibacillary Mid-Borderline Leprosy with Type 1 Lepra Reaction and Concurrent Latent Tuberculosis.
Topics: Abattoirs; Anti-Inflammatory Agents; Antitubercular Agents; Clofazimine; Dapsone; Diagnosis, Differe | 2021 |
Chronic, persistent angioedema and sinusitis-like presentation of multibacillary leprosy.
Topics: Adolescent; Angioedema; Biopsy; Chronic Disease; Clofazimine; Dapsone; Developing Countries; Diagnos | 2018 |
Case Report: A Case of Type 1 Leprosy Reaction and Dapsone Hypersensitivity Syndrome Complicating the Clinical Course of Multibacillary Leprosy.
Topics: Dapsone; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Leprostatic Agents; Lepro | 2019 |
A young man with livid facial nodules and a loss of eyebrows.
Topics: Adult; Alopecia; Clofazimine; Dapsone; Eyebrows; Facial Dermatoses; Humans; Leprostatic Agents; Lepr | 2013 |
Dapsone and body mass index in subjects with multibacillary leprosy.
Topics: Adult; Body Mass Index; Chromatography, High Pressure Liquid; Dapsone; Humans; Leprostatic Agents; L | 2014 |
[Borderline lepromatous leprosy].
Topics: Adult; Biopsy; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Leprosy, Borderline; | 2014 |
Is drug-resistant Mycobacterium leprae a real cause for concern?: First approach to molecular monitoring of multibacillary Colombian patients with and without previous leprosy treatment.
Topics: Adolescent; Adult; Bacterial Proteins; Biopsy; Child; Colombia; Dapsone; DNA, Bacterial; Drug Resist | 2014 |
Six years' follow-up of multibacillary leprosy patients treated with uniform multi-drug therapy in China.
Topics: Adolescent; Adult; Aged; Child; China; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Foll | 2015 |
Nonpruritic erythematous plaques.
Topics: Adult; Animals; Armadillos; Biopsy; Clofazimine; Dapsone; Diagnosis, Differential; Drug Therapy, Com | 2009 |
Clinical-pathological conference: case 3.
Topics: Adult; Dapsone; Diagnosis, Differential; Drug Therapy, Combination; Humans; Immunologic Deficiency S | 2010 |
Relapse study in smear positive multibacillary (MB) leprosy after 1 year WHO-multi-drug therapy (MDT) in Cebu, Philippines.
Topics: Adolescent; Adult; Aged; Child; Clofazimine; Dapsone; Drug Therapy, Combination; Female; Humans; Lep | 2011 |